B. McLaughlin

发表

Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer.

David S. K. Lu, H. Scher, M. Fleisher, 2017, European urology.

Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making.

Zachary J. Heins, P. Kantoff, B. Taylor, 2017, JCO precision oncology.

Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.

David S. K. Lu, H. Vargas, H. Scher, 2016, JAMA oncology.

Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer

David S. K. Lu, H. Scher, Yipeng Wang, 2018, JAMA oncology.

Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer.

David S. K. Lu, H. Vargas, H. Scher, 2017, Cancer research.

Title : Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer

David S. K. Lu, H. Vargas, H. Scher, 2017 .

Monitoring Integration over Time Supports a Role for Cytotoxic T Lymphocytes and Ongoing Replication as Determinants of Reservoir Size

S. Migueles, M. Connors, F. Hecht, 2016, Journal of Virology.

AR-V7 and CTC heterogeneity biomarkers additively to predict patient (pt) outcomes with taxanes relative to approved AR targeted therapy.

David S. K. Lu, H. Scher, Yipeng Wang, 2016 .